Company intelligence / Profile preview
Celcuity Inc.
Minneapolis, Minnesota, United Statescelcuity.com ↗
- Ownership
- Public · CELC
- Employees
- ~87
- Development stage
- Other
01
Overview
Celcuity is conducting a Phase 3 registration-enabling clinical trial (VIKTORIA-2) to evaluate gedatolisib in patients with HR+/HER2- advanced breast cancer. The trial is expected to begin enrolling patients in the second quarter of 2025[7][8].
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Pfizer Inc. (license agreement for gedatolisib)[6]
04
Financials
- Market cap
- $3.1B
- Total revenue
- $0
- Enterprise value
- $3.7B
Beyond the preview
Go deeper on Celcuity Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celcuity Inc..